ArticleStem cell reviews and reports2011
In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells.
Article in Stem cell reviews and reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age.Stem cells and development · 2015Trial
- Amniotic fluid collected from vaginal birth as a source of stem cells for clinical applications and disease modeling.Stem cells translational medicine · 2025Article
- Review
- Recent Advances in Scaffolding from Natural-Based Polymers for Volumetric Muscle Injury.Molecules (Basel, Switzerland) · 2021Review
- Characteristics and Therapeutic Potential of Human Amnion-Derived Stem Cells.International journal of molecular sciences · 2021Review
- Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.Frontiers in cell and developmental biology · 2021Article
- Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease.International journal of molecular sciences · 2020Review
- Cross talk between mesenchymal and glioblastoma stem cells: Communication beyond controversies.Stem cells translational medicine · 2020Review
- Amniotic Fluid Cells, Stem Cells, and p53: Can We Stereotype p53 Functions?International journal of molecular sciences · 2019Review
- Cardiomyocytes Derived from HumanScientific reports · 2018Article
- Human Adipose-Derived and Amniotic Fluid-Derived Stem Cells: A Preliminary In Vitro Study Comparing Myogenic Differentiation Capability.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Cardiac Restoration Stemming From the Placenta Tree: Insights From Fetal and Perinatal Cell Biology.Frontiers in physiology · 2018Review
- Endothelial growth medium suppresses apoptosis of mesenchymal stem cells in vitro via decrease of miR‑29a.Molecular medicine reports · 2017Article
- The transplantation of Akt-overexpressing amniotic fluid-derived mesenchymal stem cells protects the heart against ischemia-reperfusion injury in rabbits.Molecular medicine reports · 2016Article
- Amniotic Fluid Stem Cells: A Novel Source for Modeling of Human Genetic Diseases.International journal of molecular sciences · 2016Review
- Differentiation of Enhanced Green Fluorescent Protein-Labeled Mouse Amniotic Fluid-Derived Stem Cells into Cardiomyocyte-Like Beating Cells.Acta Cardiologica Sinica · 2015Article
- Capillary-like network formation by human amniotic fluid-derived stem cells within fibrin/poly(ethylene glycol) hydrogels.Tissue engineering. Part A · 2015Article
- Perinatal stem cells: A promising cell resource for tissue engineering of craniofacial bone.World journal of stem cells · 2015Review
- Human Amniotic Fluid Mesenchymal Stem Cells from Second- and Third-Trimester Amniocentesis: Differentiation Potential, Molecular Signature, and Proteome Analysis.Stem cells international · 2015Article
- Nanoscale Control of Silks for Nanofibrous Scaffold Formation with Improved Porous Structure.Journal of materials chemistry. B · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Cell therapy has developed as a complementary treatment for myocardial regeneration. While both autologous and allogeneic uses have been advocated, the ideal candidate has not been identified yet. Amniotic fluid-derived stem (AFS) cells are potentially a promising resource for cell therapy and tissue engineering of myocardial injuries. However, no information is available regarding their use in an allogeneic context. c-kit-sorted, GFP-positive rat AFS (GFP-rAFS) cells and neonatal rat cardiomyocytes (rCMs) were characterized by cytocentrifugation and flow cytometry for the expression of mesenchymal, embryonic and cell lineage-specific antigens. The activation of the myocardial gene program in GFP-rAFS cells was induced by co-culture with rCMs. The stem cell differentiation was evaluated using immunofluorescence, RT-PCR and single cell electrophysiology. The in vivo potential of Endorem-labeled GFP-rAFS cells for myocardial repair was studied by transplantation in the heart of animals with ischemia/reperfusion injury (I/R), monitored by magnetic resonance imaging (MRI). Three weeks after injection a small number of GFP-rAFS cells acquired an endothelial or smooth muscle phenotype and to a lesser extent CMs. Despite the low GFP-rAFS cells count in the heart, there was still an improvement of ejection fraction as measured by MRI. rAFS cells have the in vitro propensity to acquire a cardiomyogenic phenotype and to preserve cardiac function, even if their potential may be limited by poor survival in an allogeneic setting.
Indexed as
Identifiers
21120638What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.